Adamis Pharmaceuticals Corporation Company Profile (NASDAQ:ADMP)

About Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation logoAdamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $163.03 million
  • Outstanding Shares: 31,351,000
Average Prices:
  • 50 Day Moving Avg: $5.02
  • 200 Day Moving Avg: $4.59
  • 52 Week Range: $2.40 - $6.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.33
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $11.39 million
  • Price / Sales: 14.45
  • Book Value: $1.22 per share
  • Price / Book: 4.30
Profitability:
  • EBIDTA: ($18,970,000.00)
  • Net Margins: -158.51%
  • Return on Equity: -69.03%
  • Return on Assets: -47.51%
Debt:
  • Debt-to-Equity Ratio: 0.08%
  • Current Ratio: 2.19%
  • Quick Ratio: 2.04%
Misc:
  • Average Volume: 622,322 shs.
  • Beta: 0.05
  • Short Ratio: 5.87
 

Frequently Asked Questions for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

What is Adamis Pharmaceuticals Corporation's stock symbol?

Adamis Pharmaceuticals Corporation trades on the NASDAQ under the ticker symbol "ADMP."

How were Adamis Pharmaceuticals Corporation's earnings last quarter?

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.41) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.48) by $0.07. The company had revenue of $2.08 million for the quarter. Adamis Pharmaceuticals Corporation had a negative net margin of 158.51% and a negative return on equity of 69.03%. View Adamis Pharmaceuticals Corporation's Earnings History.

When will Adamis Pharmaceuticals Corporation make its next earnings announcement?

Adamis Pharmaceuticals Corporation is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Adamis Pharmaceuticals Corporation.

Where is Adamis Pharmaceuticals Corporation's stock going? Where will Adamis Pharmaceuticals Corporation's stock price be in 2017?

3 brokers have issued 12-month price objectives for Adamis Pharmaceuticals Corporation's shares. Their predictions range from $5.00 to $13.00. On average, they anticipate Adamis Pharmaceuticals Corporation's stock price to reach $8.33 in the next twelve months. View Analyst Ratings for Adamis Pharmaceuticals Corporation.

What are analysts saying about Adamis Pharmaceuticals Corporation stock?

Here are some recent quotes from research analysts about Adamis Pharmaceuticals Corporation stock:

  • 1. Maxim Group analysts commented, "Adamis reported the second quarter (10Q) 2017, with revenues of $3.8M and a net loss of $4.9M for the period. The 10Q shows that the company ended the period with $11.8M in cash. However, our understanding is that the company now has close to $25M in cash as a result of cash brought in from warrant holders associated with the last financing." (8/21/2017)
  • 2. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (3/21/2017)

Who are some of Adamis Pharmaceuticals Corporation's key competitors?

Who are Adamis Pharmaceuticals Corporation's key executives?

Adamis Pharmaceuticals Corporation's management team includes the folowing people:

  • Richard C. Williams, Independent Chairman of the Board
  • Dennis J. Carlo Ph.D., President, Chief Executive Officer, Director
  • Robert O. Hopkins, Chief Financial Officer, Vice President - Finance
  • David J. Marguglio, Senior Vice President - Corporate Development, Director
  • Karen K. Daniels, Vice President - Operations
  • Gus Fernandez Pharm.D., Vice President - Commercial Operations
  • Thomas Moll Ph.D., Vice President - Research
  • William Charles Denby III, Independent Director
  • Robert B. Rothermel, Independent Director

Who owns Adamis Pharmaceuticals Corporation stock?

Adamis Pharmaceuticals Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.42%), EAM Investors LLC (0.85%), Bard Associates Inc. (0.56%), Leisure Capital Management (0.53%), Sterling Global Strategies LLC (0.26%) and Northern Trust Corp (0.19%). View Institutional Ownership Trends for Adamis Pharmaceuticals Corporation.

Who sold Adamis Pharmaceuticals Corporation stock? Who is selling Adamis Pharmaceuticals Corporation stock?

Adamis Pharmaceuticals Corporation's stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC. View Insider Buying and Selling for Adamis Pharmaceuticals Corporation.

Who bought Adamis Pharmaceuticals Corporation stock? Who is buying Adamis Pharmaceuticals Corporation stock?

Adamis Pharmaceuticals Corporation's stock was purchased by a variety of institutional investors in the last quarter, including EAM Investors LLC, Vanguard Group Inc., IFP Advisors Inc, Wells Fargo & Company MN, Sterling Global Strategies LLC, First Allied Advisory Services Inc., Virtu KCG Holdings LLC and Leisure Capital Management. View Insider Buying and Selling for Adamis Pharmaceuticals Corporation.

How do I buy Adamis Pharmaceuticals Corporation stock?

Shares of Adamis Pharmaceuticals Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamis Pharmaceuticals Corporation's stock price today?

One share of Adamis Pharmaceuticals Corporation stock can currently be purchased for approximately $5.25.


MarketBeat Community Rating for Adamis Pharmaceuticals Corporation (NASDAQ ADMP)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  170
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.33 (58.73% upside)

Analysts' Ratings History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/12/2017Raymond James Financial, Inc.Initiated CoverageOutperform$7.00HighView Rating Details
8/21/2017Maxim GroupReiterated RatingBuy$13.00HighView Rating Details
1/24/2017B. RileyReiterated RatingBuy$5.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Earnings by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Earnings History by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ ADMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017        
11/14/2016Q3 2016($0.48)($0.41)$2.08 millionViewN/AView Earnings Details
8/15/2016Q2($0.37)$1.93 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
2017 EPS Consensus Estimate: ($0.69)
2018 EPS Consensus Estimate: ($0.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.16)($0.16)($0.16)
Q4 20171($0.16)($0.16)($0.16)
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.11)($0.11)($0.11)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 10.14%
Insider Trades by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Institutional Ownership by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Insider Trades by Quarter for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2016David J MarguglioVPSell700$9.00$6,300.00View SEC Filing  
5/16/2016David J MarguglioSVPSell4,000$8.08$32,320.00View SEC Filing  
5/9/2016David J MarguglioSVPSell4,860$10.00$48,600.00View SEC Filing  
5/4/2016David J MarguglioSVPSell4,860$9.17$44,566.20View SEC Filing  
5/3/2016David J MarguglioSVPSell1,140$9.00$10,260.00View SEC Filing  
4/14/2016David J MarguglioSVPSell12,000$7.52$90,240.00View SEC Filing  
8/14/2015Robert B RothermelDirectorBuy7,000$3.33$23,310.00View SEC Filing  
4/20/2015David J MarguglioSVPSell200$5.00$1,000.00View SEC Filing  
4/14/2015David J MarguglioSVPSell2,200$5.01$11,022.00View SEC Filing  
3/4/2015David J MarguglioSVPSell11,800$7.09$83,662.00View SEC Filing  
3/2/2015David J MarguglioSVPSell7,000$6.45$45,150.00View SEC Filing  
2/13/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell12,076$6.41$77,407.16View SEC Filing  
2/12/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell38,000$6.40$243,200.00View SEC Filing  
2/3/2015Ahmed Shayan Fazlur RahmanMajor ShareholderSell30,000$6.75$202,500.00View SEC Filing  
1/5/2015David J MarguglioVPSell7,000$6.18$43,260.00View SEC Filing  
12/30/2014David J MarguglioSVPSell12,228$6.09$74,468.52View SEC Filing  
12/29/2014David J MarguglioVPSell772$6.00$4,632.00View SEC Filing  
12/12/2014David J MarguglioSVPSell4,000$5.18$20,720.00View SEC Filing  
9/2/2014William C DenbyDirectorBuy2,500$5.06$12,650.00View SEC Filing  
8/29/2014Robert B RothermelDirectorBuy5,500$4.03$22,165.00View SEC Filing  
6/2/2014David J MarguglioSVPSell4,000$5.56$22,240.00View SEC Filing  
8/14/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell7,015$0.57$3,998.55View SEC Filing  
8/7/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell40,000$0.56$22,400.00View SEC Filing  
8/2/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell67,960$0.57$38,737.20View SEC Filing  
7/30/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell10,328$0.56$5,783.68View SEC Filing  
7/26/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell95,000$0.56$53,200.00View SEC Filing  
7/23/2013Ahmed Shayan Fazlur RahmanMajor ShareholderSell141,224$0.57$80,497.68View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Latest Headlines for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Adamis Pharmaceuticals Corp. : September 18, 2017
finance.yahoo.com - September 18 at 8:56 PM
americanbankingnews.com logoAdamis Pharmaceuticals Corporation (ADMP) Now Covered by Raymond James Financial, Inc.
www.americanbankingnews.com - September 12 at 6:58 PM
finance.yahoo.com logoETFs with exposure to Adamis Pharmaceuticals Corp. : September 7, 2017
finance.yahoo.com - September 7 at 3:23 PM
finance.yahoo.com logoETFs with exposure to Adamis Pharmaceuticals Corp. : September 7, 2017
finance.yahoo.com - September 7 at 3:23 PM
finance.yahoo.com logoAdamis Pharmaceuticals Corp. :ADMP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017
finance.yahoo.com - September 6 at 3:26 PM
seekingalpha.com logoAdamis Pharmaceuticals: Updates To Thesis - Seeking Alpha
seekingalpha.com - August 27 at 1:29 AM
benzinga.com logoAdamis Pharmaceuticals Attempts To Extend 4-Day Winning Streak
www.benzinga.com - August 23 at 9:10 PM
benzinga.com logoMylan's Stock Is No Longer A Buy According To Analysts At Argus - Benzinga
www.benzinga.com - August 22 at 9:02 PM
americanbankingnews.com logoAdamis Pharmaceuticals Corporation (ADMP) Rating Reiterated by Maxim Group
www.americanbankingnews.com - August 21 at 4:08 PM
americanbankingnews.com logoFinancial Review: Sanofi (SNY) versus Adamis Pharmaceuticals Corp (ADMP)
www.americanbankingnews.com - August 17 at 12:14 AM
nasdaq.com logoStonebridge Capital Advisors LLC Buys Gilead Sciences Inc, Microsoft Corp, SPDR S&P 500, ...
www.nasdaq.com - August 16 at 3:27 PM
americanbankingnews.com logoShort Interest in Adamis Pharmaceuticals Corporation (ADMP) Drops By 36.7%
www.americanbankingnews.com - August 12 at 1:44 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corporation (ADMP) and Juniper Pharmaceuticals (JNP) Critical Review
www.americanbankingnews.com - August 2 at 10:14 PM
prnewswire.com logoTechnical Reports on Drug Delivery Equities -- PetMed Express, Adamis Pharma ...
www.prnewswire.com - July 14 at 5:18 PM
americanbankingnews.com logoZacks: Adamis Pharmaceuticals Corporation (ADMP) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - July 10 at 2:20 PM
americanbankingnews.com logoZacks: Adamis Pharmaceuticals Corporation (ADMP) Given $10.00 Average Target Price by Analysts
www.americanbankingnews.com - June 23 at 8:40 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corporation (ADMP) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - June 17 at 8:34 AM
nasdaq.com logoADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good ... - Nasdaq
www.nasdaq.com - June 16 at 3:42 PM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) Announces FDA Approval for Epinephrine Pre-Filled Syringe
www.streetinsider.com - June 16 at 2:00 AM
rttnews.com logoADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good Spirits
www.rttnews.com - June 16 at 2:00 AM
finance.yahoo.com logoAdamis Pharma stock skyrockets after rival EpiPen product gets FDA approval
finance.yahoo.com - June 16 at 2:00 AM
finance.yahoo.com logoAdamis Pharmaceuticals (ADMP): Third Time Is The Charm
finance.yahoo.com - June 16 at 2:00 AM
finance.yahoo.com logoPRESS DIGEST - Wall Street Journal - June 16
finance.yahoo.com - June 16 at 2:00 AM
nasdaq.com logoHealth Care Sector Update for 06/15/2017: ADMP,SKLN,QBIO - Nasdaq
www.nasdaq.com - June 15 at 8:50 PM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) Announces FDA Approval for Epinephrine Pre-Filled Syringe - StreetInsider.com
www.streetinsider.com - June 15 at 8:50 PM
finance.yahoo.com logoFDA approves new, cheaper rival to EpiPen allergy shot
finance.yahoo.com - June 15 at 8:50 PM
finance.yahoo.com logo[$$] Adamis Obtains FDA Approval for Epinephrine Treatment
finance.yahoo.com - June 15 at 8:50 PM
finance.yahoo.com logoA Peek At Adamis Ahead Of FDA Approval
finance.yahoo.com - June 15 at 3:45 PM
finance.yahoo.com logoAdamis Pharmaceuticals Receives FDA Approval for Its Epinephrine Pre-Filled Syringe
finance.yahoo.com - June 15 at 3:45 PM
americanbankingnews.com logoCritical Contrast: Adamis Pharmaceuticals Corporation (ADMP) versus Galena Biopharma (GALE)
www.americanbankingnews.com - June 13 at 4:48 PM
americanbankingnews.com logoMaxim Group Reaffirms Buy Rating for Adamis Pharmaceuticals Corporation (ADMP)
www.americanbankingnews.com - June 12 at 1:48 PM
americanbankingnews.com logo Adamis Pharmaceuticals Corp (ADMP) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - June 8 at 8:12 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - June 6 at 10:26 PM
seekingalpha.com logoAdamis Pharmaceuticals: Strong Buy Before Huge Potential Catalyst ... - Seeking Alpha
seekingalpha.com - June 2 at 1:30 AM
finance.yahoo.com logoCould This Tiny Biotech Be the David to Mylan's Epipen Goliath?
finance.yahoo.com - May 26 at 3:29 PM
americanbankingnews.com logo Adamis Pharmaceuticals Corp (ADMP) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 24 at 2:34 PM
americanbankingnews.com logoZacks: Adamis Pharmaceuticals Corp (ADMP) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 24 at 2:34 PM
finance.yahoo.com logoBetting on Adamis Pharmaceuticals and Ocular Therapeutix Ahead of FDA Decisions
finance.yahoo.com - May 8 at 11:24 AM
americanbankingnews.com logo Adamis Pharmaceuticals Corp (ADMP) Given $7.50 Consensus Price Target by Analysts
www.americanbankingnews.com - May 5 at 9:18 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Given Media Sentiment Rating of -0.25
www.americanbankingnews.com - May 2 at 10:08 AM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Given News Impact Rating of -0.12
www.americanbankingnews.com - April 29 at 9:00 AM
finance.yahoo.com logoAdamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
finance.yahoo.com - April 26 at 8:31 PM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Given Media Impact Score of 0.29
www.americanbankingnews.com - April 26 at 12:50 PM
americanbankingnews.com logoAdamis Pharmaceuticals Corp (ADMP) Receiving Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 23 at 7:38 AM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) Prices 4.3M Shares at $3.50 - StreetInsider.com
www.streetinsider.com - April 22 at 3:20 PM
streetinsider.com logoPre-Open Movers 04/21: (OCN) (VBLT) (PFPT) Higher; (XBIT) (ADMP) (EFII) (MAT) Lower (more...)
www.streetinsider.com - April 21 at 8:20 PM
nasdaq.com logoMid-Day Market Update: CAI International Gains On Strong Results; Adamis Pharmaceuticals Shares Slide - Nasdaq
www.nasdaq.com - April 21 at 3:19 PM
streetinsider.com logoAdamis Pharmaceuticals (ADMP) to Offer Common Stock - StreetInsider.com
www.streetinsider.com - April 21 at 3:19 PM
finance.yahoo.com logoAdamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 21 at 3:19 PM
finance.yahoo.com logoAdamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - April 20 at 8:29 PM

Social

Chart

Adamis Pharmaceuticals Corporation (ADMP) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff